ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2023
Validation of the EQ-5D-5L and psychosocial bolt-ons in a large cohort of people living with multiple sclerosis in Australia.
Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Performance of EQ5D-5L and AHPEQS for measuring outcomes and experiences of patients with peripherally inserted central catheters: a secondary analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Trial
- Updated Health Economics Simulation Model of the Lifetime Progression of Multiple Sclerosis in an Australian Setting.PharmacoEconomics - open · 2026Article
- Impact of long COVID on diverse Australian populations: a multi-site, longitudinal prospective cohort study protocol.BMJ open · 2026Article
- "Getting to diagnosis was an absolute nightmare": survey insights about the lived experience of spinal CSF leak in Australia and Aotearoa New Zealand.Journal of neurology · 2026Article
- Assessing the reliability and validity of the Italian EQ-5D-5 L in multiple sclerosis: a cross-sectional study.Journal of patient-reported outcomes · 2026Article
- Psychometric validation of a cognition and social participation bolt-on for the EQ-5D-5L in SARS-CoV-2 infected German healthcare workers.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Identifying and developing EQ-5D-5L bolt-on items for Chinese chronic obstructive pulmonary disease patients.Health and quality of life outcomes · 2025Article
- Societal Versus Healthcare Perspectives on the Cost Effectiveness of Ocrelizumab for Treatment of Primary Progressive Multiple Sclerosis in Aotearoa New Zealand.PharmacoEconomics · 2025Article
- An AI-Based Telerehabilitation Solution to Improve Mobility in People With Multiple Sclerosis (the PLATINUMS Project): Protocol for an Implementation and Evaluation Study.JMIR research protocols · 2025Article
- Effect of impairment on health-related quality of life in people with multiple sclerosis: association of functional systems and EQ-5D-5L index values in a cross-sectional study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Article
- Article
- The Health-Related Quality of Life Impact of the COVID-19 Pandemic on People Living with Multiple Sclerosis and the General Population: A Comparative Study Utilizing the EQ-5D-5L with Psychosocial Bolt-Ons.Brain and behavior · 2025Article
- Article
- Health-Related Quality of Life in Romanian Patients with Dystonia: An Exploratory Study.Journal of clinical medicine · 2024Article
- Article
- Assessing health state utilities for people with myalgic encephalomyelitis/chronic fatigue syndrome in Australia using the EQ-5D-5L, AQoL-8D and EQ-5D-5L-psychosocial instruments.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Estimating the disutility of relapse in relapsing-remitting and secondary progressive multiple sclerosis using the EQ-5D-5L, AQoL-8D, EQ-5D-5L-psychosocial, and SF-6D: implications for health economic evaluation models.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Article
- Parent-Reported Child and Parent Quality of Life during COVID-19 Testing at an Australian Paediatric Hospital Outpatient Clinic: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2023Article
- Higher diet quality is associated with short and long-term benefits on SF-6D health state utilities: a 5-year cohort study in an international sample of people with multiple sclerosis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundMultiple sclerosis (MS) is an inflammatory, neurodegenerative disease of the central nervous system which results in disability over time and reduced quality of life. To increase the sensitivity of the EQ-5D-5L for psychosocial health, four bolt-on items from the AQoL-8D were used to create the nine-item EQ-5D-5L-Psychosocial. We aimed to externally validate the EQ-5D-5L-Psychosocial in a large cohort of people with MS (pwMS) and explore the discriminatory power of the new instrument with EQ-5D-5L/AQoL-8D.
methodsA large representative sample from the Australian MS Longitudinal Study completed the AQoL-8D and EQ-5D-5L (including EQ VAS) and both instruments health state utilities (HSUs) were scored using Australian tariffs. Sociodemographic/clinical data were also collected. External validity of EQ-5D-5L-Psychosocial scoring algorithm was assessed with mean absolute errors (MAE) and Spearman's correlation coefficient. Discriminatory sensitivity was assessed with an examination of ceiling/floor effects, and disability severity classifications.
resultsAmong 1683 participants (mean age: 58.6 years; 80% female), over half (55%) had moderate or severe disability. MAE (0.063) and the distribution of the prediction error were similar to the original development study. Mean (± standard deviation) HSUs were EQ-5D-5L: 0.58 ± 0.32, EQ-5D-5L-Psychosocial 0.62 ± 0.29, and AQoL-8D: 0.63 ± 0.20. N = 157 (10%) scored perfect health (i.e. HSU = 1.0) on the EQ-5D-5L, but reported a mean HSU of 0.90 on the alternative instruments. The Sleep bolt-on dimension was particularly important for pwMS.
conclusionsThe EQ-5D-5L-Psychosocial is more sensitive than the EQ-5D-5L in pwMS whose HSUs approach those reflecting full health. When respondent burden is taken into account, the EQ-5D-5L-Psychosocial is preferential to the AQoL-8D. We suggest a larger confirmatory study comparing all prevalent multi-attribute utility instruments for pwMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.